Pharmaceuticals, Biotechnology and Life Sciences
Azitra will be presenting results from the joint researchshowing the successful genetic engineering of the common skin bacterium, Staphylococcusepidermidis, to produce high levels of functional LEKTI protein, aprotease inhibitor involved in regulating the rate of skin loss.
QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing…
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).
Eventhough you have probably heard that you have to let acne run its course, dermatologists disagree. Dermatologists explain that acne, if not treated, leave dark spots and permanent scars on the skin.
Everyone gets an itch once in a while. Usually it only lasts for a short time and is often caused by annoyances like a mosquito bite or scratchy fabric. However, if an itch lasts for more than six weeks, say dermatologists from the American Academy of Dermatology, it is considered a chronic itch and is more likely to disrupt your life.
Novartis has entered into a definitive agreement to buy a privately held company Ziarco Group Limited, focused on producing dermatology…
Amryt, the clinical-stage specialty pharmaceutical company focused on fighting rare and orphan diseases, has raised a five-year €20m loan with…
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.